Document is current
Any future updates will be listed below
-
Authors
Olsson, Lisa M. https://orcid.org/0000-0001-9730-1915
Borgeraas, Heidi
Chakaroun, Rima M. https://orcid.org/0000-0001-9901-1815
Hofsø, Dag
Hertel, Jens Kristoffer https://orcid.org/0000-0002-8693-7018
Dwibedi, Chinmay https://orcid.org/0000-0001-6416-4440
Mitteregger, Matthias https://orcid.org/0000-0002-0703-6415
Holst, Jens Juul https://orcid.org/0000-0001-6853-3805
Tremaroli, Valentina https://orcid.org/0000-0002-9150-4233
Hjelmesæth, Jøran https://orcid.org/0000-0002-1995-0562
Bäckhed, Fredrik https://orcid.org/0000-0002-4871-8818
- License Information
-
More Information
Article History
Received: 10 December 2025
Accepted: 31 March 2026
First Online: 7 May 2026
Competing interests
: F.B. is co-founder and shareholder of Roxbiosens and Implexion Pharma and receives research funding from Biogaia and Novo Nordisk. L.M.O. and V.T. are co-founders and shareholders of Roxbiosens. The other authors declare no competing interests.
